Larmark Pharmaceutical Private Limited - Company Profile

It is a pharma private limited company based in South 24 Parganas, West Bengal, India, established in 2010.
2010 South 24 Parganas, West Bengal, India Active
Last Updated:
Access Report
About Larmark Pharmaceutical Private Limited

Larmark Pharmaceutical Private Limited, a active private limited company, was established on 27 May 2010 in South 24 Parganas, West Bengal, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U74900WB2010PTC149728. Registered under ROC Roc Kolkata. it is unlisted. It has an authorized capital of ₹4.00 M and a paid-up capital of ₹4.00 M.

Formerly known as La- Marck Pharmaceutical Private Limited. It upholds a compliant status. Employing 30 professional, Its leadership includes Moinak Basu (Director), Chaitali Basu (Director), Maitree Basu (Additional Director). Past directors included Ranendra Kumar Bose, Samarendra Kumar Basu, Dwipendra Kumar Bose. It holds ₹1.29 Cr open charges and no settled loans. Its latest AGM occurred on 26 September 2025, with the balance sheet filed on 31 March 2025. It is based at 18/2, Pranabananda Road, Ground Floor,, Ward No. 110. P.O Garia, P.S Patuli, South 24 Parganas, West Bengal, 700084.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U74900WB2010PTC149728

  • Registration Number

    149728

  • Incorporation Date

    27 May 2010

  • Authorized Capital

    ₹4.00 M

  • Paid-Up Capital

    ₹4.00 M

  • ROC Code

    Roc Kolkata

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 4.00 M
  • Paid Up Capital ₹ 4.00 M
  • Company Age 15 Year, 9 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 1.29 Cr
  • Revenue Growth **** -16.62%
  • Profit Growth **** -82.29%
  • Ebitda **** 435.78%
  • Net Worth 2.09%
  • Total Assets **** 31.94%
Company report

Larmark Pharmaceutical Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Larmark Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Larmark Pharmaceutical Private Limited?
Current Directors
Name Designation Appointment Date Status
Moinak Basu Director 12 Apr 2016 Current
Chaitali Basu Director 03 Aug 2022 Current
Maitree Basu Additional Director 28 Dec 2023 Current
Parna Saha Basu Additional Director 28 Dec 2023 Current
Samarendra Kumar Basu Additional Director 02 Nov 2023 Current
Biswa Nath Pal Director 20 Jan 2018 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 07 Jun 2021 Past
Pramod Abcsdd Director 01 Aug 2022 Past
Pramod Abcsdd Director 19 Oct 2013 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Larmark Pharmaceutical.

Larmark Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 16.62% decrease. The company also saw a substantial fall in profitability, with a 82.29% decrease in profit. The company's net worth moved up by a moderate rise of 2.09%.

Larmark Pharmaceutical revenue growth over time
Larmark Pharmaceutical profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -16.62%
*******
*******
*******
*******
Revenue from Operations
*******
 -14.62%
*******
*******
*******
*******
Total Assets
*******
 31.94%
*******
*******
*******
*******
Profit or Loss
*******
 -82.29%
*******
*******
*******
*******
Net Worth
*******
 2.09%
*******
*******
*******
*******
EBITDA
*******
 435.78%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Larmark Pharmaceutical?

In 2023, Larmark Pharmaceutical had a public holding of 19.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹12,900,000.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • Hdfc Bank Limited : 0.60 Cr
  • Axis Bank Limited : 0.44 Cr
  • Bank Of India : 0.25 Cr
Latest Charge Details
Date Lender Amount Status
23 Feb 2024 Axis Bank Limited ₹0.80 M Open
20 Sep 2023 Axis Bank Limited ₹3.60 M Open
20 Aug 2022 Hdfc Bank Limited ₹6.00 M Open
26 Sep 2011 Bank Of India ₹2.50 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Larmark Pharmaceutical?

Larmark Pharmaceutical has a workforce of 30 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Larmark Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Larmark Pharmaceutical's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Larmark Pharmaceutical
Recent Activity within the Organization
  • Annual General Meeting

    Larmark Pharmaceutical Private Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records. was recorded as a recent event.

  • Balance Sheet

    Larmark Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Kolkata. was recorded as a recent event.

  • Charges

    A charge with Axis Bank Limited amounted to Rs. 0.80 M with Charge ID 100876133 was registered on 23 Feb 2024. was recorded as a recent event.

  • Director Appointment

    Progress on Maitree Basu was appointed as a Additional Director was appointed as a Additional Director on 28 Dec 2023 & has been associated with this company since 2 years 2 months . was documented.

  • Director Appointment

    Parna Saha Basu was appointed as a Additional Director was appointed as a Additional Director on 28 Dec 2023 & has been associated with this company since 2 years 2 months . was recorded as a recent event.

  • Director Appointment

    The activity Samarendra Kumar Basu was appointed as a Additional Director was appointed as a Additional Director on 02 Nov 2023 & has been associated with this company since 2 years 4 months . was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Larmark Pharmaceutical Private Limited?

The CIN of Larmark Pharmaceutical Private Limited is U74900WB2010PTC149728.

Where is Larmark Pharmaceutical Private Limited headquartered?

Larmark Pharmaceutical Private Limited is headquartered at 18/2, Pranabananda Road, Ground Floor,, Ward No. 110. P.O Garia, P.S Patuli, South 24 Parganas, West Bengal, 700084.

When was Larmark Pharmaceutical Private Limited incorporated?

Larmark Pharmaceutical Private Limited was incorporated on 27 May 2010.

Who are the current directors of Larmark Pharmaceutical Private Limited?

The current directors of Larmark Pharmaceutical Private Limited are

What is the primary industry of Larmark Pharmaceutical Private Limited?

The primary industry of Larmark Pharmaceutical Private Limited is Trade.

Is Larmark Pharmaceutical Private Limited a listed company?

Larmark Pharmaceutical Private Limited is unlisted.

What is the capital structure of Larmark Pharmaceutical Private Limited?

The authorized capital of Larmark Pharmaceutical Private Limited is ₹4.00 M, and the paid-up capital is ₹4.00 M.

What is the compliance status of Larmark Pharmaceutical Private Limited?

The compliance status of Larmark Pharmaceutical Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available